JUL 20, 2016 8:00 AM PDT

Using multiplexed IHC to effectively navigate the hidden clues of the immunological microenvironment

  • Field Applications Scientist, PerkinElmer
      Dr. Stack completed his undergraduate education at Stony Brook University in Stony Brook, New York prior to his Ph.D. studies at Boston College in Chestnut Hill, Massachusetts. He carried out postdoctoral research at Boston University, where he began to develop his interests in human translational research. Dr. Stack has carried out many oncology studies examining disease mechanisms in multiple cancer types while at the Dana-Farber Cancer Institute, where he was the associate director of the Dana-Farber/Brigham and Women's Center for Molecular Oncologic Pathology, and an instructor in the Pathology Department of Brigham and Women's and the Harvard Medical School. Dr. Stack was also a member of the Dana-Farber/Harvard Cancer Center in both the gastrointestinal malignancies and prostate cancer research programs. Dr. Stack is currently a pathology scientist at PerkinElmer, where he is interested in developing cancer immunology-focused, tissue-based assays, which can provide deeper insights into cancer-host interactions and assist in clinical management of cancer.

    DATE: July 20th

    Therapies like ipilimumab and nivolumab  have shown the potential for approaches that direct the patient’s own immune system against tumors.  Further advances will require a detailed understanding of the tumor microenvironment and characterization of the location and status of immune cells and their interaction with tumor cells.  This will require methods that provide phenotyping of immune and cancer cells combined with the cytoarchitectonics of the tumor. To achieve this, a practical method for simultaneous immunohistochemistry of up to 8 biomarkers in a single tissue section using standard unlabeled primary antibodies will be described. In addition, approaches for multiplexed imaging, single cell quantitative analysis, automated phenotyping and bioinformatics that enable new insights into cancer biology and immunology will be presented. These will then be leveraged in analyses of multiple cancer types, where it is established that the host-tumor interaction is complex and difficult to characterize with standard immunohistochemistry or flow cytometry. But by leveraging multiplexed IHC in situ, we will demonstrate the unique spatial relationships of immune phenotypes in and around both epithelial and non-epithelial tumor types, and show how this data has the potential to form the basis of assays that can guide therapy and monitor response. Further data regarding functional assessment of regulatory immunologic co-factor expression will be discussed.

    Show Resources
    Show Resources
    • See more
    Connect with us